NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enanta Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $66.61 +0.95 (+1.45 %) (As of 12/13/2019 04:00 PM ET) Add Compare Today's Range$65.52Now: $66.61▼$66.7150-Day Range$59.58MA: $62.43▼$66.5152-Week Range$57.15Now: $66.61▼$106.80Volume161,079 shsAverage Volume190,104 shsMarket Capitalization$1.31 billionP/E Ratio30.14Dividend YieldN/ABeta0.9 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA Previous Symbol CUSIPN/A CIK1177648 Webhttp://www.enanta.com/ Phone617-607-0800Debt Debt-to-Equity RatioN/A Current Ratio17.77 Quick Ratio17.77Price-To-Earnings Trailing P/E Ratio30.14 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$205.20 million Price / Sales6.40 Cash Flow$2.39 per share Price / Cash Flow27.92 Book Value$23.50 per share Price / Book2.83Profitability EPS (Most Recent Fiscal Year)$2.21 Net Income$46.38 million Net Margins22.60% Return on Equity10.46% Return on Assets9.87%Miscellaneous Employees113 Outstanding Shares19,730,000Market Cap$1.31 billion Next Earnings Date2/5/2020 (Estimated) OptionableOptionable Receive ENTA News and Ratings via Email Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ENTA Rates by TradingView Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its earnings results on Thursday, November, 21st. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by $0.12. The biotechnology company had revenue of $51.30 million for the quarter, compared to analysts' expectations of $55.95 million. Enanta Pharmaceuticals had a net margin of 22.60% and a return on equity of 10.46%. The firm's quarterly revenue was down 23.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.30 earnings per share. View Enanta Pharmaceuticals' Earnings History. When is Enanta Pharmaceuticals' next earnings date? Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Enanta Pharmaceuticals. What price target have analysts set for ENTA? 4 brokerages have issued 12-month target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $101.33 in the next twelve months. This suggests a possible upside of 52.1% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals. What is the consensus analysts' recommendation for Enanta Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals. Has Enanta Pharmaceuticals been receiving favorable news coverage? News headlines about ENTA stock have been trending somewhat negative on Saturday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Enanta Pharmaceuticals. Who are some of Enanta Pharmaceuticals' key competitors? Some companies that are related to Enanta Pharmaceuticals include Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Intercept Pharmaceuticals (ICPT), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Taro Pharmaceutical Industries (TARO), Evotec (EVTCY), Alkermes (ALKS), Uniqure (QURE) and GW Pharmaceuticals PLC- (GWPH). What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), NVIDIA (NVDA), Ford Motor (F), Wells Fargo & Co (WFC), Alibaba Group (BABA) and Tesla (TSLA). Who are Enanta Pharmaceuticals' key executives? Enanta Pharmaceuticals' management team includes the folowing people: Dr. Jay R. Luly, Pres, CEO & Director (Age 63)Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53) Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.49%), Krensavage Asset Management LLC (2.53%), Man Group plc (1.50%), Granahan Investment Management Inc. MA (0.76%), Russell Investments Group Ltd. (0.49%) and Rhumbline Advisers (0.26%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals. Which major investors are selling Enanta Pharmaceuticals stock? ENTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, First Trust Advisors LP, Dupont Capital Management Corp, Alps Advisors Inc., Navellier & Associates Inc, Systematic Financial Management LP, New York State Teachers Retirement System and Barclays PLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals. Which major investors are buying Enanta Pharmaceuticals stock? ENTA stock was bought by a variety of institutional investors in the last quarter, including Man Group plc, Squarepoint Ops LLC, State Street Corp, Krensavage Asset Management LLC, SG Americas Securities LLC, Voloridge Investment Management LLC, California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for Enanta Pharmaceuticals. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $66.61. How big of a company is Enanta Pharmaceuticals? Enanta Pharmaceuticals has a market capitalization of $1.31 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals. What is Enanta Pharmaceuticals' official website? The official website for Enanta Pharmaceuticals is http://www.enanta.com/. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected] MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 264 (Vote Outperform)Underperform Votes: 302 (Vote Underperform)Total Votes: 566MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2019 by MarketBeat.com StaffFeatured Article: Return On Assets